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Poster Session II S289with a notable recent increase in utilization for Severe Aplastic
Anemia (SAA). Recent data, although limited, has suggested
that unrelated cord blood transplantation can be a successful
treatment strategy for patients with SAA lacking a well-matched
adult donor. A retrospective analysis was performed as a means
to compare the SLCBB experience (n5 42) with published re-
sults. Outcomes data was available and evaluated for 16 singleton
cord transplants. This population included 11 pediatric and 5
adult patients. The mean age was 15.4 years (1.7-45.2). Donor/
recipient HLA matching was six of six (n5 2), five of six
(n5 8), four of six (n5 6). Median total nucleated cell dose
was 7.2  107/kg. Fourteen patients received myeloablative con-
ditioning regimens while two received non-myeloablative condi-
tioning. Thirteen patients achieved neutrophil engraftment with
a median time to recovery of 21 days (9-46). The six patients
who received a total nucleated cell dose (TNC) . 5.0  107/
kg had a median time to engraftment of 20 days as compared
to 27 days for patients receiving a TNC dose\5.0  107/kg.
There was one instance of graft failure and one patient censored
due to early death. Ten patients are alive and three have expired
from infectious complications. Acute GVHD occurred in nine
patients and chronic GVHD developed in six. Outcomes for
dual cord transplants (n5 11) were available for three patients.
All three patients engrafted with a median time to absolute neu-
trophil recovery of 25 days (22-28). These findings support that
unrelated cord blood transplant is a feasible treatment strategy
for Severe Aplastic Anemia. The SLCBB will continue to track
and report outcomes for this population.354
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Introduction: Primary and post-ET/PV-myelofibrosis (MF) is
a rare myeloproliferative disorder with a very variable, on the long
term always fatal course. After allogeneic hematopoietic cell trans-
plantation (alloHCT) encouraging short term survival has been re-
ported. We present data from 57 consecutive transplants for MF in
our institution, demonstrating that close monitoring of the post-
transplant course is warranted.
Methods: Between 2000 and 2009 40 males and 17 females with pri-
mary MF (n5 48) and MF post ET or PV (n5 9) were grafted with
unmanipulated bone marrow (n5 22) or peripheral stem cells
(n5 35) from a related (n5 14) or an unrelated (n5 43) donor. Me-
dian (md) age was 54 (19-68) years. Fifteen patients (pts) had low, 28
intermediate and 14 high risk disease (Dupriez score 0, 1, 2). Karyo-
type was favorable in 35, unfavorable in 16 and unsuccessful in 6 pts.
All but four pts received intermediate intensity conditioning
(TBI(8 Gy)/Flud/Cy n5 29 or Bu(10)/Flud n5 24, standard
n5 4). In all except 4matched transplants rabbit ATGwas added be-
fore grafting.
Results: All pts engrafted at a md of 25 (11-70) days. 16 pts either
transiently or permanently lost complete chimerism during follow
up with proven relapse at a md of 376 (69 – 1211) days in 12. Overall
probability of relapse at 4 years is 32%. At a md follow up of 46 (4-
115) months probability of overall versus relapse free survival (RFS)
is 66% vs 50% for the whole cohort. Probability of RFS is signifi-
cantly less in pts with unfavorable karyotype compared to those
with favorable karyotype (21 vs 63%, p5 0.004) and for pts with cir-
culating blasts. 1% compared to those with blasts\5 1% (27 vs
61%, p5 0.002). Twelve pts with decreasing chimerism/relapse re-
ceived immunotherapy (6 PBSC boosts, 8 donor lymphocyte infu-
sions) with 8 patients responding. In 6 pts response was complete,
2 subsequently lost their response and 5 ultimately had to receive
a second transplant
Conclusions: Our results underscore the need for closely moni-
toring MF pts after alloHCT. Problems with loss of donor chi-
merism and relapse post-transplant are common however maywell respond to cellular immunotherapy. For full evaluation of
the role of alloHCT in the management of MF long term results
are warranted.355
ADDITION OF BUSULFAN TO FLUDARABINE AND TOTAL BODY IRRADIA-
TION CONDITIONED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION ENHANCES DONOR T-CELL ENGRAFTMENT AND
OPTIMIZES DISEASE CONTROL
Meyers, G., Subbiah, N., Palmbach, G., Dunn, A., Abar, F., Hayes-
Lattin, B., Gajewski, J., Kovacsovics, T., Slater, S., Jacoby, C.,
Allen, B., Maziarz, R. Oregon Health and Science University, Portland,
OR
While nonmyeloablative allogeneic hematopoietic stem cell trans-
plantation (HSCT) is associated with a reduction in treatment asso-
ciated toxicity, limitations in disease control continue to impact
overall outcomes. Key to optimizing disease remission is the rapid
integration of the donor T cell compartment to maximize graft vs.
malignancy activity. While details on the kinetics of engraftment
in nonmyeloablative HSCT is limited, reports by two groups (Baron
F. et al, Blood, 2004,104:2254 and Saito B. et al, BBMT, 2008
14:1148) concur that low donor T-cell chimerisms by Day +30 por-
tend poorer outcomes from either disease progression or engraft-
ment failure. Therefore, manipulation of the transplant procedure
to optimize engraftment outcomes early in the post-transplant
course is vital to maximize outcomes. To this end, we established
an institutional reduced-intensity regimen of busulfan 3.2 mg/kg
IV, fludarabine 90 mg/m2 and TBI 2 Gy followed by allogeneic pe-
ripheral blood stem cell transplant. Our GVHD prophylaxis regi-
men includes cyclosporine and MMF. This report describes our
early T cell chimerism data in 76 patients and shows a correlation be-
tween T cell chimerism and disease control.
The mean percentage of donor CD3+ cells was 72% at Day +28,
98% at Day +56 and 99.9% at Day +84, which compare favorably
to previous reports of engraftment with fludarabine and TBI alone.
We further analyzed chimerism data in those patients with measur-
able disease going into transplant and those with early relapse despite
remission at the time of transplant. In 13 patients that were not in
complete remission at the time of transplant, but subsequently
achieved complete remission, the mean CD3+ donor cells at Day
+28 was 85% and 92% at Day +56. This is in stark contrast to the
group of 7 patients who were in complete remission at the time of
transplant, but rapidly relapsed post-transplant, with a mean Day
+28 CD3+ donor cells of 57%, with minimal improvement to an av-
erage of 63% at Day +56, statistically significantly different from the
group achieving remission. Additional findings with this regimen in-
clude 2 year survival of 49%, with acceptable levels of GVHD.
The addition of busulfan to the backbone of fludarabine and TBI
enhances early T cell engraftment, leading to optimal disease control
by harnessing graft vs. malignancy activity. Early poor T cell chime-
risms may define those at high-risk of relapse, prompting interven-
tions to enrich donor T cell constitution.356
TARGETED IV BUSULFAN AND FLUDARABINE FOLLOWED BY POST-AL-
LOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION RITUXIMAB DEM-
ONSTRATE ENCOURAGING ACTIVITY IN HIGH RISK CD20 + POSITIVE
LYMPHOID MALIGNANCIES WITHOUT INCREASED INFECTIOUS COMPLI-
CATIONS
Roman-Diaz, J.L., Pidala, J., Nishihori, T., Perkins, J., Tate, C.,
Ochoa, J., Ayala, E., Fernandez, H.F., Anasetti, C., Kharfan-
Dabaja, M.A. Moffitt Cancer Center, Tampa, FL
Rituximab has activity in lymphoid malignancies and may aug-
ment responses after allogeneic hematopoietic cell transplantation
(HCT); however prolonged lymphopenia may increase the risk
for infectious complications. We examined the safety of Rituximab
after reduced toxicity conditioning HCT. Sixteen patients (median
age 56, range 35 – 68), (CLL 7, follicular lymphoma 4, mantle cell
lymphoma3, and large cell lymphoma 2 with CD20 positive lym-
phoid malignancies. Twelve had a partial response and 4 complete
